Table 5

External responsiveness of disease activity measures in patients with primary Sjögren's syndrome treated with rituximab

ESSPRI
Outcome		Baseline	Δ0–16	Δ0–24	Δ0–36	Δ0–48	Δ0–60
ESSDAI	ρ	−0.056	0.011	−0.010	0.117	0.088	0.139
ESSDAI	ρ	0.777	0.954	0.962	0.569	0.682	0.356
Patient's GDA	ρ	0.620	0.431	0.315	0.525	0.393	0.623
Patient's GDA	ρ	0.000	0.022	0.110	0.006	0.058	0.001
Physician's GDA	ρ	0.349	0.088	0.255	0.116	0.062	0.103
Physician's GDA	ρ	0.069	0.657	0.200	0.574	0.772	0.625
IgM-Rf	ρ	0.090	0.117	0.187	0.306	0.379	0.324
IgM-Rf	ρ	0.650	0.552	0.349	0.128	0.058	0.115
SWS	ρ	−0.036	−0.005	0.128	−0.174	−0.288	−0.285
SWS	ρ	0.855	0.981	0.524	0.395	0.172	0.199

ESSDAI
Outcome		Baseline	Δ0–16	Δ0–24	Δ0–36	Δ0–48	Δ0–60
Patient's GDA	ρ	0.145	0.349	0.350	0.121	0.395	0.509
Patient's GDA	ρ	0.463	0.068	0.068	0.539	0.037	0.007
Physician's GDA	ρ	0.378	0.389	0.435	0.500	0.743	0.736
Physician's GDA	ρ	0.047	0.041	0.021	0.007	0.000	0.000
IgM-Rf	ρ	−0.082	−0.122	−0.225	0.094	−0.141	−0.125
IgM-Rf	ρ	0.677	0.536	0.250	0.635	0.476	0.533
SWS	ρ	−0.137	−0.203	0.029	0.175	−0.029	−0.066
SWS	ρ	0.486	0.309	0.882	0.372	0.882	0.758

Δ0–16, change from baseline to 16 weeks; Δ0–24, change from baseline to 24 weeks; Δ0–36, change from baseline to 36 weeks; Δ0–48, change from baseline to 48 weeks; Δ0–60, change from baseline to 60 weeks.
ESSDAI, EULAR Sjögren's Syndrome Disease Activity Index; ESSPRI, EULAR Sjögren's Syndrome Patients Reported Index; GDA, global disease activity assessment; IgM-Rf, rheumatoid factor; SWS, stimulated whole salivary flow.